Literature DB >> 10713597

The role of the hepatitis C virus glycoproteins in infection.

M Flint1, J A McKeating.   

Abstract

HCV encodes two glycoproteins, E1 and E2, that are believed to be exposed on the surface of virions. These molecules are likely to be involved in viral interactions with the host immune response and responsible for mediating viral entry into target cells. They are obvious major components for prototype vaccine studies. Recently, E2 has been reported to bind to the tetraspan molecule CD81, which represents a putative receptor for HCV. Here, we discuss the role the HCV gps may play during infection, the contribution of E2 gp variation to HCV evasion from the immune response and possible implications of the E2-CD81 interaction for HCV pathogenesis. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713597     DOI: 10.1002/(sici)1099-1654(200003/04)10:2<101::aid-rmv268>3.0.co;2-w

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  24 in total

1.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.

Authors:  Fang Chen; Yinglan Zhao; Min Liu; Dongqing Li; Hongyan Wu; Haidan Chen; Yongzhe Zhu; Fengling Luo; Jin Zhong; Yidan Zhou; Zhongtian Qi; Xiao-Lian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 3.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

4.  Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro.

Authors:  Mostafa K El-Awady; Ashraf A Tabll; Khaled Atef; Samar S Yousef; Moataza H Omran; Yasmin El-Abd; Noha G Bader-Eldin; Ahmad M Salem; Samir F Zohny; Wael T El-Garf
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

Review 5.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

6.  L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.

Authors:  Jason P Gardner; Robert J Durso; Robert R Arrigale; Gerald P Donovan; Paul J Maddon; Tatjana Dragic; William C Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

7.  Extrahepatic manifestations of hepatitis C virus (HCV).

Authors:  David G Samuel; Ian W Rees
Journal:  Frontline Gastroenterol       Date:  2013-05-24

8.  CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2.

Authors:  Fang Chen; Yilan Hu; Dongqing Li; Haidan Chen; Xiao-Lian Zhang
Journal:  PLoS One       Date:  2009-12-03       Impact factor: 3.240

9.  Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81.

Authors:  Zhan-Fei Tian; Hong Shen; Xi-Hua Fu; Yi-Chun Chen; Hubert E Blum; Thomas F Baumert; Xi-Ping Zhao
Journal:  World J Gastroenterol       Date:  2009-01-14       Impact factor: 5.742

Review 10.  Novel therapies in hepatitis B and C.

Authors:  Bart Takkenberg; Joep de Bruijne; Christine Weegink; Peter Jansen; Hendrik Reesink
Journal:  Curr Gastroenterol Rep       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.